The US Food and Drug Administration (FDA) has expanded the approval of ipilimumab (Yervoy) to include the treatment of pediatric melanoma patients 12 years and older with unresectable or metastatic disease.
Data-driven screening guidelines for skin cancer have been published electronically, in reaction to the U.S. Preventive Services Task Force’s 2016 draft recommendation statement on skin cancer screening.
Extracorporeal photopheresis is underused for early-stage mycosis fungoides. ECP is capable of correcting the cytokine imbalance seen in patients with MF and results in an increase of Th1 cytokines. Clinicians should consider more frequent use in select patients
Laser for melanoma in situ (MIS) should generally be reserved for nonsurgical, usually elderly patients. When indicated, MIS may be treated with CO2 laser or with combined Q-switched Nd:YAG and imiquimod. Any atypical-appearing lesion should be biopsied prior to the start of a laser treatment.
The May Table of the Month goes over tips for properly diagnosing skin cancer types.
Dermatologists should be versed and informed about the specific attitudes and lifestyle habits that could be fueling rising skin cancer risk in the Hispanic population, according to dermatologist Maritza I. Perez, M.D.
Cyclosporine and PUVA clearly increase the risk of squamous cell carcinomas, and there is evidence that TNF blockers and methotrexate may do so to a lesser degree. UVB phototherapy has not been shown to cause skin cancer. Acitretin offers protection against the development of basal cell and squamous cell carcinomas.
Today’s SRT technology embodies very small, stable machines. Radiation leaks are not longer a concern. The SRT-100 System serves both an important medical and cosmetic role.
About one third of the more than 118,000 people who received free skin cancer screenings from the AAD’s SPOTme program in 2009 and 2010 indicated they had recently seen a change in the size, shape or color of a mole.
Newer tools to help diagnose challenging lesions include combined immunohistochemical stains and a growing array of genetic tests, one of which has shown the potential to gauge metastatic risk.